Events
9 events
GLP-16 outcomes · closes in 7 months
First GLP-1 telehealth to raise a mega-round in 2026
- Hims55%
- Sequence (Weight Watchers)53%
- Found50%
- + 3 more
GLP-14 outcomes · closes in 8 months
Tirzepatide compounding outcome
- Full ban with no shortage carve-out57%
- Status quo (compounding continues)49%
- Expanded permissions46%
- + 1 more
GLP-16 outcomes · closes in 9 months
First GLP-1 brand to 1M active subscribers
- Ro52%
- Sequence51%
- Found50%
- + 3 more
GLP-16 outcomes · closes in 9 months
First retailer to launch private-label GLP-1 program 2026
- Walgreens55%
- Costco54%
- Mark Cuban Cost Plus51%
- + 3 more
GLP-16 outcomes · closes in 11 months
Most-funded GLP-1 weight-loss app of 2026
- Ro Body52%
- Sequence (WW)50%
- Other49%
- + 3 more
GLP-14 outcomes · closes in 11 months
Cardiovascular GLP-1 indication approval 2026
- Wegovy (semaglutide)50%
- Zepbound (tirzepatide)49%
- Neither in 202647%
- + 1 more
GLP-16 outcomes · closes in 11 months
GLP-1 telehealth that consolidates first in 2026
- Calibrate52%
- No consolidation50%
- Sequence49%
- + 3 more
GLP-13 outcomes · closes in 12 months
Lilly vs Novo: bigger GLP-1 share gain in 2026
- Tied within 1pp54%
- Novo Nordisk (semaglutide)50%
- Eli Lilly (tirzepatide)48%
GLP-15 outcomes · closes in 12 months
Generic GLP-1 launch in US
- Q2 202654%
- 2027 or later53%
- Q3 202653%
- + 2 more